DOCSLIB.ORG

KIR3DL1 and HLA-B Density and Binding Calibrate NK Education and Response to HIV

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
KIR3DL1 and HLA-B Density and Binding Calibrate NK Education and Response to HIV KIR3DL1 and HLA-B Density and Binding Calibrate NK Education and Response to HIV This information is current as Jeanette E. Boudreau, Tiernan J. Mulrooney, Jean-Benoît Le of September 25, 2021. Luduec, Edward Barker and Katharine C. Hsu J Immunol 2016; 196:3398-3410; Prepublished online 9 March 2016; doi: 10.4049/jimmunol.1502469 http://www.jimmunol.org/content/196/8/3398 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2016/03/08/jimmunol.150246 Material 9.DCSupplemental http://www.jimmunol.org/ References This article cites 72 articles, 37 of which you can access for free at: http://www.jimmunol.org/content/196/8/3398.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 25, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology KIR3DL1 and HLA-B Density and Binding Calibrate NK Education and Response to HIV Jeanette E. Boudreau,*,1 Tiernan J. Mulrooney,* Jean-Benoıˆt Le Luduec,* Edward Barker,† and Katharine C. Hsu*,‡,x NK cells recognize self-HLA via killer Ig-like receptors (KIR). Homeostatic HLA expression signals for inhibition via KIR, and downregulation of HLA, a common consequence of viral infection, allows NK activation. Like HLA, KIR are highly polymorphic, and allele combinations of the most diverse receptor–ligand pair, KIR3DL1 and HLA-B, correspond to hierarchical HIV control. We used primary cells from healthy human donors to demonstrate how subtype combinations of KIR3DL1 and HLA-B calibrate NK education and their consequent capacity to eliminate HIV-infected cells. High-density KIR3DL1 and Bw4-80I partnerships endow NK cells with the greatest reactivity against HLA-negative targets; NK cells exhibiting the remaining KIR3DL1/HLA-Bw4 combinations demonstrate intermediate responsiveness; and Bw4-negative KIR3DL1+ NK cells are poorly responsive. Cytotox- Downloaded from icity against HIV-infected autologous CD4+ T cells strikingly correlated with reactivity to HLA-negative targets. These findings suggest that the programming of NK effector function results from defined features of receptor and ligand subtypes. KIR3DL1 and HLA-B subtypes exhibit an array of binding strengths. Like KIR3DL1, subtypes of HLA-Bw4 are expressed at distinct, predictable membrane densities. Combinatorial permutations of common receptor and ligand subtypes reveal binding strength, receptor density, and ligand density to be functionally important. These findings have immediate implications for prognosis in patients with HIV infection. Furthermore, they demonstrate how features of KIR and HLA modified by allelic variation calibrate http://www.jimmunol.org/ NK cell reactive potential. The Journal of Immunology, 2016, 196: 3398–3410. atural killer cells weigh inhibitory input against acti- specific for self-HLA class I molecules readily respond to acti- vating signals to distinguish healthy from diseased cells vation signals on target cells when HLA is absent or downregu- N (1, 2). To simultaneously achieve self-tolerance and lated (3, 5–7). In contrast, uneducated NK cells lacking inhibitory sensitivity to unhealthy cells, NK cells rely on interaction between receptors for self–class I molecules require more potent stimula- cell surface killer Ig-like receptors (KIR) and their HLA class I tion, including inflammation or opsonizing Abs, to be activated for ligands. KIR receptors convey inhibitory signaling upon binding effector function, but their insensitivity to inhibition by class I by guest on September 25, 2021 to their HLA ligands, thereby preventing autoaggression. Of in- molecules is beneficial in conditions in which HLA expression terest, KIR and HLA interaction is also critical for NK education, persists (8–10). a poorly understood process that confers NK cell sensitivity to loss Among individuals with the same KIR and HLA genes, NK of normal HLA expression on diseased cells. Independent segre- populations frequently exhibit dramatic differences in inhibitory gation of KIR and HLA genes frequently leads to the same indi- sensitivities and reactive potentials, possibly attributable to sig- vidual harboring NK populations exhibiting KIR for self-HLA as nificant allelic variation for both receptor and ligand (11–14). well as NK populations exhibiting KIR for which the cognate li- KIR3DL1 and HLA-B form the most ancient and polymorphic gand is lacking (3, 4). Educated cells expressing KIR molecules receptor–ligand pair (15). Wide variation in KIR3DL1 and HLA-B alleles occurs throughout global populations, but both genes are maintained at nearly 100% frequency, underscoring a coevolution *Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065; †Department of Immunology and Microbiology, Rush that has selected for substantial subtype diversity (16). University Medical Center, Chicago, IL 60612; ‡Department of Medicine, Memorial x The 77 unique alleles of KIR3DL1 are classified into 4 subtypes Sloan Kettering Cancer Center, New York, NY 10065; and Weill Cornell Medical based on their surface expression density and sequence homology: College, New York, NY 10065 KIR3DS1, null (KIR3DL1-n), low (KIR3DL1-l), and high (KIR3DL1-h) 1Current address: Department of Microbiology and Immunology, Dalhousie Univer- sity, Halifax, NS, Canada. (17–19). Considerably more diverse, the HLA-B alleles can ORCIDs: 0000-0002-9187-7128 (J.E.B.); 0000-0002-0218-2771 (T.J.M.). nevertheless be clustered based on polymorphisms at positions Received for publication November 23, 2015. Accepted for publication February 8, 77–83 that define either the Bw6 epitope, which does not interact 2016. with any KIR, or the Bw4 epitope, a ligand for KIR3DL1 (20). This work was supported by National Institutes of Health Grants R01 HL088134, Based on a dimorphism (isoleucine versus threonine) at position U01 AI069197, P01 CA23766, P30 CA008748-46, P03 CA008748 (Memorial Sloan 80 that affects interaction with KIR3DL1, the HLA-Bw4 alleles Kettering Cancer Center Core Grant), and R01 AI065361 (to E.B.). can be segregated further into Bw4-80I or Bw4-80T subtypes. Address correspondence and reprint requests to Dr. Katharine C. Hsu, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, In experiments using transfectant systems and tetramer bind- NY 10065. E-mail address: [email protected] ing, specific combinations of KIR3DL1 and HLA-Bw4 subtypes The online version of this article contains supplemental material. exhibit different receptor–ligand binding affinities and inhibitory Abbreviations used in this article: KIR, killer Ig-like receptor; b2m, b2-microglobu- strengths (13, 14, 21). KIR3DS1 and KIR3DL1-n subtypes are lin; MFI, median fluorescence intensity; MSKCC, Memorial Sloan Kettering Cancer not known to engage Bw4 molecules on neighboring cells; Center; PCR-SSP, PCR with sequence-specific primers. however, specific peptides, including those from HIV, may fa- Copyright Ó 2016 by The American Association of Immunologists, Inc. 0022-1767/16/$30.00 cilitate engagement of KIR3DS1 by Bw4-80I (22). KIR3DL1-l www.jimmunol.org/cgi/doi/10.4049/jimmunol.1502469 The Journal of Immunology 3399 and -h subtypes, in contrast, bind both Bw4 subtypes, with -Bw6, -C1, and -C2 subtypes using the HLA Immunopolymorphism data- varying strengths. KIR3DL1*005, a common KIR3DL1-l iso- base version 3.14.0. KIR genotyping and KIR3DL1 subtyping were form, binds Bw4-80I and -80T tetramers with similar affinity performed as previously described (19, 31, 32). Individuals with KIR3DL1*002-group high alleles were examined using a Luminex-based (21). KIR3DL1-h, notably the common KIR3DL1*001 and *015 KIR SSO platform according to the manufacturer’s instructions. The probe isoforms, preferentially engage Bw4-80I over -80T tetramers recognition site for bead region 64 spans the codons 236–239 and specif- (13, 21, 23). The functional relevance of such preferential ically targets the alleles KIR3DL1*002 and KIR3DL1*054. KIR3DL1*054 binding remains to be determined in primary NK cells, in which is a rare allele, lacking entirely from at least two patient cohorts (33, 34). Therefore, individuals positive for bead region 64 by Luminex and additional factors, including receptor and ligand densities, might KIR3DL1*002-group typing by PCR with sequence-specific primers (PCR- influence cell–cell interactions and NK education. SSP) were assumed to exhibit KIR3DL1*002. KIR3DL1*002 and *015 Combinations of KIR3DL1 and HLA-B subtypes are associated represent a total of 70.2% of the alleles identified in the KIR3DL1*002 with distinct rates of disease progression in persons infected with HIV group by PCR-SSP. Therefore, alleles not identified as KIR3DL1*002 in (24). Notably, pairings of Bw4-80I with KIR3DL1-h, -n, or KIR3DS1 this group
Load more

Recommended publications
  • Expression Tissue
    The Journal of Immunology Killer Cell Ig-Like Receptor and Leukocyte Ig-Like Receptor Transgenic Mice Exhibit Tissue- and Cell-Specific Transgene Expression1 Danny Belkin,* Michaela Torkar,* Chiwen Chang,* Roland Barten,* Mauro Tolaini,† Anja Haude,* Rachel Allen,* Michael J. Wilson,* Dimitris Kioussis,† and John Trowsdale2* To generate an experimental model for exploring the function, expression pattern, and developmental regulation of human Ig-like activating and inhibitory receptors, we have generated transgenic mice using two human genomic clones: 52N12 (a 150-Kb clone encompassing the leukocyte Ig-like receptor (LILR)B1 (ILT2), LILRB4 (ILT3), and LILRA1 (LIR6) genes) and 1060P11 (a 160-Kb clone that contains ten killer cell Ig-like receptor (KIR) genes). Both the KIR and LILR families are encoded within the leukocyte receptor complex, and are involved in immune modulation. We have also produced a novel mAb to LILRA1 to facilitate expression studies. The LILR transgenes were expressed in a similar, but not identical, pattern to that observed in humans: LILRB1 was expressed in B cells, most NK cells, and a small number of T cells; LILRB4 was expressed in a B cell subset; and LILRA1 was found on a ring of cells surrounding B cell areas on spleen sections, consistent with other data showing monocyte/macrophage expression. KIR transgenic mice showed KIR2DL2 expression on a subset of NK cells and T cells, similar to the pattern seen in humans, and expression of KIR2DL4, KIR3DS1, and KIR2DL5 by splenic NK cells. These observations indicate that linked regulatory elements within the genomic clones are sufficient to allow appropriate expression of KIRs in mice, and illustrate that the presence of the natural ligands for these receptors, in the form of human MHC class I proteins, is not necessary for the expression of the KIRs observed in these mice.
    [Show full text]
  • Phyre 2 Results for A1YIY0
    Email [email protected] Description A1YIY0 Tue Jul 30 13:19:15 BST Date 2013 Unique Job 1035bc4b501530df ID Detailed template information # Template Alignment Coverage 3D Model Confidence % i.d. Template Information PDB header:cell adhesion Chain: A: PDB Molecule:down syndrome cell adhesion molecule 1 c3dmkA_ Alignment 100.0 14 (dscam) isoform PDBTitle: crystal structure of down syndrome cell adhesion molecule (dscam)2 isoform 1.30.30, n-terminal eight ig domains PDB header:cell adhesion 2 c2om5A_ Alignment 100.0 20 Chain: A: PDB Molecule:contactin 2; PDBTitle: n-terminal fragment of human tax1 PDB header:cell adhesion 3 c3jxaA_ Alignment 100.0 21 Chain: A: PDB Molecule:contactin 4; PDBTitle: immunoglobulin domains 1-4 of mouse cntn4 PDB header:signaling protein/transferase Chain: A: PDB Molecule:tek tyrosine kinase variant; 4 c4k0vA_ 100.0 12 Alignment PDBTitle: structural basis for angiopoietin-1 mediated signaling initiation PDB header:immune system Chain: A: PDB Molecule:natural cytotoxicity triggering receptor 1; 5 c1p6fA_ 100.0 9 Alignment PDBTitle: structure of the human natural cytotoxicity receptor nkp46 PDB header:immune system/receptor 6 c1ollA_ Alignment 99.9 9 Chain: A: PDB Molecule:nk receptor; PDBTitle: extracellular region of the human receptor nkp46 PDB header:viral protein Chain: A: PDB Molecule:hoc head outer capsid protein; 7 c3shsA_ 99.9 18 Alignment PDBTitle: three n-terminal domains of the bacteriophage rb49 highly immunogenic2 outer capsid protein (hoc) PDB header:immune system Chain: E: PDB Molecule:natural
    [Show full text]
  • Differential Integrin Adhesome Expression Defines Human Natural
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.01.404806; this version posted December 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Differential integrin adhesome expression defines human natural killer cell residency and developmental stage Everardo Hegewisch Solloa1, Seungmae Seo1, Bethany L. Mundy-Bosse2, Anjali Mishra3,a, Erik Waldman4,b, Sarah Maurrasse4,b, Eli Grunstein4, Thomas J. Connors5, Aharon G. Freud2,6, and Emily M. Mace1 1Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York NY 10032 2Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210 33Division of Dermatology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210 4Department of Otolaryngology - Head and Neck Surgery, Columbia University Medical Center, New York, New York 10032 5Department of Pediatrics, Division of Pediatric Critical Care and Hospital Medicine, Columbia University Irving Medical Center, New York, NY 10024 6Department of Pathology, The Ohio State University, Columbus,
    [Show full text]
  • Snipa Snpcard
    SNiPAcard Block annotations Block info genomic range chr19:55,117,749-55,168,602 block size 50,854 bp variant count 74 variants Basic features Conservation/deleteriousness Linked genes μ = -0.557 [-4.065 – AC009892.10 , AC009892.5 , AC009892.9 , AC245036.1 , AC245036.2 , phyloP 2.368] gene(s) hit or close-by AC245036.3 , AC245036.4 , AC245036.5 , AC245036.6 , LILRA1 , LILRB1 , LILRB4 , MIR8061 , VN1R105P phastCons μ = 0.059 [0 – 0.633] eQTL gene(s) CTB-83J4.2 , LILRA1 , LILRA2 , LILRB2 , LILRB5 , LILRP1 μ = -0.651 [-4.69 – 2.07] AC008984.5 , AC008984.5 , AC008984.6 , AC008984.6 , AC008984.7 , AC008984.7 , AC009892.10 , AC009892.10 , AC009892.2 , AC009892.2 , AC009892.5 , AC010518.3 , AC010518.3 , AC011515.2 , AC011515.2 , AC012314.19 , AC012314.19 , FCAR , FCAR , FCAR , FCAR , FCAR , FCAR , FCAR , FCAR , FCAR , FCAR , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 ,
    [Show full text]
  • Crystal Structure of the HLA-Cw3 Allotype-Specific Killer Cell Inhibitory Receptor KIR2DL2
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 3864–3869, March 1999 Immunology Crystal structure of the HLA-Cw3 allotype-specific killer cell inhibitory receptor KIR2DL2 GREG A. SNYDER*, ANDREW G. BROOKS†, AND PETER D. SUN‡§ *Department of Biochemistry, Molecular Biology, and Cell Biology, 2153 Sheridan, O. T. Hogan Hall, Room 2-100, Northwestern University, Evanston, IL 60208; †Department of Microbiology and Immunology, University of Melbourne, Royal Parade, Parkville, 3052 Victoria, Australia; and ‡Structural Biology Section, Office of the Scientific Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 12441 Parklawn Drive, Rockville, MD 20852 Edited by David R. Davies, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, and approved January 19, 1999 (received for review November 11, 1998) ABSTRACT Killer cell inhibitory receptors (KIR) protect differ primarily in the transmembrane and the intracellular class I HLAs expressing target cells from natural killer (NK) regions. KIR2DL molecules are inhibitory receptors possess- cell-mediated lysis. To understand the molecular basis of this ing intracellular immunoreceptor tyrosine-based inhibitory receptor-ligand recognition, we have crystallized the extra- motifs (ITIM), whereas KIR2DS molecules appear to be cellular ligand-binding domains of KIR2DL2, a member of the noninhibitory receptors with shorter intracellular tails that Ig superfamily receptors that recognize HLA-Cw1, 3, 7, and 8 interact with an immunoreceptor tyrosine-based activation allotypes. The structure was determined in two different motif (ITAM) containing signaling component DAP12 (11). crystal forms, an orthorhombic P212121 and a trigonal P3221 KIR3D members have three Ig domains (known as D0, D1, space group, to resolutions of 3.0 and 2.9 Å, respectively.
    [Show full text]
  • Cytolytic Activity of NK Cell Clones Against Acute Childhood Precursor
    Bone Marrow Transplantation (2009) 43, 875–881 & 2009 Macmillan Publishers Limited All rights reserved 0268-3369/09 $32.00 www.nature.com/bmt ORIGINAL ARTICLE Cytolytic activity of NK cell clones against acute childhood precursor-B-cell leukaemia is influenced by HLA class I expression on blasts and the differential KIR phenotype of NK clones T Feuchtinger1, M Pfeiffer1, A Pfaffle1, H-M Teltschik1, D Wernet2, M Schumm1, R Lotfi2, R Handgretinger1 and P Lang1 1Department of Paediatric Haematology/Oncology, University Children’s Hospital, Tu¨bingen, Germany and 2Institute of Transfusion Medicine, Eberhard Karls University, Tu¨bingen, Germany Relapse after allo-SCT in patients with acute leukaemia Introduction remains a major problem. A beneficial impact of alloreactive natural killer (NK) cells has been reported Stem cell transplantation from matched or partially for myeloid malignancies, but has been questionable for matched unrelated donors as well as mismatched related B-lineage ALL. We analysed lysis of primary paediatric donors has become an established procedure for the precursor-B-ALL blasts by 285 NK cell clones to treatment of children with high risk and relapsed leukae- investigate whether HLA class I expression on the blasts mia.1–3 GVHD-related mortality has been reduced signifi- and phenotypic killer cell Ig-like receptor (KIR) expres- cantly by T-cell depletion, but relapse still remains the sion on NK cells affect the lytic activity against ALL major problem after successful transplantation.4,5 In blasts. Precursor-B-ALL blasts with low HLA-I expres- contrast to myeloid malignancies, controversial effects of sion were lysed by a majority (79%) of NK cell clones, T-cell depletion on relapse rate in ALL have been whereas those with high HLA-I expression showed low reported.1,3,6,7 As normal numbers of NK cells reconstitute susceptibility to NK clones independent of their KIR from donor progenitors within a few weeks after T-cell expression patterns.
    [Show full text]
  • High-Dimensional Analysis Reveals a Distinct Population of Adaptive-Like Tissue
    bioRxiv preprint doi: https://doi.org/10.1101/2019.12.20.883785; this version posted December 20, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 High-dimensional analysis reveals a distinct population of adaptive-like tissue- 2 resident NK cells in human lung 3 4 Nicole Marquardt1*, Marlena Scharenberg1, Jeffrey E. Mold2, Joanna Hård2, Eliisa 5 Kekäläinen3,4, Marcus Buggert1, Son Nguyen5,6, Jennifer N. Wilson1, Mamdoh Al- 6 Ameri7, Hans-Gustaf Ljunggren1, Jakob Michaëlsson1 7 8 Running title: Adaptive-like human lung tissue-resident NK cells 9 10 Affiliations: 11 1Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, 12 Stockholm, Sweden 13 2Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden 14 3Translational Immunology Research Program & Department of Bacteriology and 15 Immunology, University of Helsinki, Finland 16 4HUSLAB, Division of Clinical Microbiology, Helsinki University Hospital, Helsinki, 17 Finland, 18 5Department of Microbiology, Perelman School of Medicine, University of 19 Pennsylvania, Philadelphia, PA, USA 20 6Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, 21 Philadelphia, PA, USA 22 7Thoracic Surgery, Department of Molecular Medicine and Surgery, Karolinska 23 Institutet, Karolinska University Hospital, Stockholm, Sweden 24 1 bioRxiv preprint doi: https://doi.org/10.1101/2019.12.20.883785; this version posted December 20, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Type of the Paper (Article
    Supplementary figures and tables E g r 1 F g f2 F g f7 1 0 * 5 1 0 * * e e e * g g g * n n n * a a a 8 4 * 8 h h h * c c c d d d * l l l o o o * f f f * n n n o o o 6 3 6 i i i s s s s s s e e e r r r p p p x x x e e e 4 2 4 e e e n n n e e e g g g e e e v v v i i i t t t 2 1 2 a a a l l l e e e R R R 0 0 0 c o n tro l u n in fla m e d in fla m e d c o n tro l u n in fla m e d in fla m e d c o n tro l u n in fla m e d in fla m e d J a k 2 N o tc h 2 H if1 * 3 4 6 * * * e e e g g g n n n a a * * a * h h * h c c c 3 * d d * d l l l * o o o f f 2 f 4 n n n o o o i i i s s s s s s e e e r r 2 r p p p x x x e e e e e e n n n e e 1 e 2 g g g e e 1 e v v v i i i t t t a a a l l l e e e R R R 0 0 0 c o n tro l u n in fla m e d in fla m e d c o n tro l u n in fla m e d in fla m e d c o n tro l u n in fla m e d in fla m e d Z e b 2 C d h 1 S n a i1 * * 7 1 .5 4 * * e e e g g g 6 n n n * a a a * h h h c c c 3 * d d d l l l 5 o o o f f f 1 .0 * n n n * o o o i i i 4 * s s s s s s e e e r r r 2 p p p x x x 3 e e e e e e n n n e e e 0 .5 g g g 2 e e e 1 v v v i i i t t t a a a * l l l e e e 1 * R R R 0 0 .0 0 c o n tro l u n in fla m e d in fla m e d c o n tro l u n in fla m e d in fla m e d c o n tro l u n in fla m e d in fla m e d M m p 9 L o x V im 2 0 0 2 0 8 * * * e e e * g g g 1 5 0 * n n n * a a a * h h h * c c c 1 5 * 6 d d d l l l 1 0 0 o o o f f f n n n o o o i i i 5 0 s s s s s s * e e e r r r 1 0 4 3 0 p p p * x x x e e e * e e e n n n e e e 2 0 g g g e e e 5 2 v v v i i i t t t a a a l l l 1 0 e e e R R R 0 0 0 c o n tro l u n in fla m e d in fla m e d c o n tro l u n in fla m e d in fla m e d c o n tro l u n in fla m e d in fla m e d Supplementary Figure 1.
    [Show full text]
  • Natural Killer Cell Lymphoma Shares Strikingly Similar Molecular Features
    Leukemia (2011) 25, 348–358 & 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11 www.nature.com/leu ORIGINAL ARTICLE Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic cd T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro J Iqbal1, DD Weisenburger1, A Chowdhury2, MY Tsai2, G Srivastava3, TC Greiner1, C Kucuk1, K Deffenbacher1, J Vose4, L Smith5, WY Au3, S Nakamura6, M Seto6, J Delabie7, F Berger8, F Loong3, Y-H Ko9, I Sng10, X Liu11, TP Loughran11, J Armitage4 and WC Chan1, for the International Peripheral T-cell Lymphoma Project 1Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA; 2Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA; 3Departments of Pathology and Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China; 4Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA; 5College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA; 6Departments of Pathology and Cancer Genetics, Aichi Cancer Center Research Institute, Nagoya University, Nagoya, Japan; 7Department of Pathology, University of Oslo, Norwegian Radium Hospital, Oslo, Norway; 8Department of Pathology, Centre Hospitalier Lyon-Sud, Lyon, France; 9Department of Pathology, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea; 10Department of Pathology, Singapore General Hospital, Singapore and 11Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA, USA Natural killer (NK) cell lymphomas/leukemias are rare neo- Introduction plasms with an aggressive clinical behavior.
    [Show full text]
  • Restoring Natural Killer Cell Immunity Against Multiple Myeloma in the Era of New Drugs
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Institutional Research Information System University of Turin Restoring Natural Killer Cell immunity against Multiple Myeloma in the era of New Drugs Gianfranco Pittari1, Luca Vago2,3, Moreno Festuccia4,5, Chiara Bonini6,7, Deena Mudawi1, Luisa Giaccone4,5 and Benedetto Bruno4,5* 1 Department of Medical Oncology, National Center for Cancer Care and Research, HMC, Doha, Qatar, 2 Unit of Immunogenetics, Leukemia Genomics and Immunobiology, IRCCS San Raffaele Scientific Institute, Milano, Italy, 3 Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy, 4 Department of Oncology/Hematology, A.O.U. Città della Salute e della Scienza di Torino, Presidio Molinette, Torino, Italy, 5 Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy, 6 Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milano, Italy, 7 Vita-Salute San Raffaele University, Milano, Italy Transformed plasma cells in multiple myeloma (MM) are susceptible to natural killer (NK) cell-mediated killing via engagement of tumor ligands for NK activating receptors or “missing-self” recognition. Similar to other cancers, MM targets may elude NK cell immunosurveillance by reprogramming tumor microenvironment and editing cell surface antigen repertoire. Along disease continuum, these effects collectively result in a pro- gressive decline of NK cell immunity, a phenomenon increasingly recognized as a critical determinant of MM progression. In recent years, unprecedented efforts in drug devel- opment and experimental research have brought about emergence of novel therapeutic interventions with the potential to override MM-induced NK cell immunosuppression.
    [Show full text]
  • KIR3DL1 and HLA-A and HLA-B Peptide-Dependent Interactions Between Cutting Edge: Allele-Specific
    Cutting Edge: Allele-Specific and Peptide-Dependent Interactions between KIR3DL1 and HLA-A and HLA-B This information is current as Hathairat Thananchai, Geraldine Gillespie, Maureen P. of September 29, 2021. Martin, Arman Bashirova, Nobuyo Yawata, Makoto Yawata, Philippa Easterbrook, Daniel W. McVicar, Katsumi Maenaka, Peter Parham, Mary Carrington, Tao Dong and Sarah Rowland-Jones J Immunol 2007; 178:33-37; ; Downloaded from doi: 10.4049/jimmunol.178.1.33 http://www.jimmunol.org/content/178/1/33 References This article cites 28 articles, 12 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/178/1/33.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 29, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. THE JOURNAL OF IMMUNOLOGY CUTTING EDGE Cutting Edge: Allele-Specific and Peptide-Dependent Interactions between KIR3DL1 and HLA-A and HLA-B1,2 † ‡ Hathairat Thananchai,* Geraldine Gillespie,* Maureen P.
    [Show full text]
  • Recombinant Proteins & Monoclonal Antibodies
    www.nkmaxbio.com NK CELL Recombinant Proteins & Monoclonal Antibodies "에이티젠"이 "엔케이맥스"로 새롭게 시작합니다. Products for NK Cell Surface Receptor Natural killer cells or NK cells are a type of cytotoxic lymphocyte critical to the innate immune system. NK cell receptors can also be differentiated based on function. Natural killer cell activation is determined by the balance of inhibitory and activating receptor stimulation. Key receptors on human NK cells KIR2DS4 HLA-C NKG2C HLA-E Activating NKG2D MIC-A/B, ULBP Receptor CD16 lgG NKp30 B7-H6 NKp44 Viral HA KIR2DL1 HLA-C NKG2A HLA-E NK cell Inhibitory Target cell KIR3DL1 HLA-BW4, HLA-A Receptor TIGIT CD112, CD113, CD155 KLRG1 Cadherins DNAM-1 CD112, CD155 NTB-A NTB-A/SLAMF6 Coreceptor LAIR-1 Collagen 2B4 CD48 Related Monoclonal Antibodies Product name Cat No. Clone No. Applications Isotype Host NKp44 ATGA0322 AT1G6 ELISA, WB, FACS, ICC/IF IgG2a, k M KIR2DS4 AKR0504 5F2 ELISA, WB IgG2b, k M KLRD1 ATGA0487 AT13E3 ELISA, WB, FACS IgG1, k M Activating NKp46 AKR0408 n1D9 ELISA, WB, FACS IgG1, k M KIR2DL1 AKR0620 2F9 ELISA, WB, FACS, ICC/IF IgG2a, k M KIR2DL3 AKR3006 190IIC311 ELISA, WB, ICC/IF IgG2a, k M Inhibitory KIR2DL4 AKR0501 2H6 ELISA, WB IgG2b, k M KIR2DL1 antibody(2F9) KIR2DL3 antibody(190IIC311) NKp46 antibody(n1D9) Cat No. AKR0620 Cat No. AKR3006 Cat No. AKR0408 ICC/IF analysis ICC/IF analysis Flow Cytometry ICC/IF analysis of KIR2DL1 in Hep3B ICC/IF analysis of KIR2DL3 in HeLa Flow cytometry analysis of NKp46 in cells line, stained with DAPI (Blue) for cells line, stained with DAPI (Blue) for HeLa cell, staining at 2-5μg for 1x106 nucleus staining and monoclonal nucleus staining and monoclonal cells (Red) with mouse anti-lgG (Blue), anti-human KIR2DL1 antibody (1:100) anti-human KIR2DL3 antibody (1:100) goat anti-mouse lgG-Alexa flour 488.
    [Show full text]